SF3B1 and prostate carcinoma: This multifaceted association of SF3B1 expression with global splicing and expression levels of key PDAC genes converges with recent data linking PDAC malignancy to splicing dysregulation [11], strongly suggesting that SF3B1 overexpression in PDAC, like in prostate cancer [16] and hepatocarcinoma [17], may have pathological consequences.